Tremblay Catherine, Friedmann Dominique
1 Department of Dermatology, Saint-Luc Hospital, Montreal University, Montréal, QC, Canada.
J Cutan Med Surg. 2017 Sep/Oct;21(5):449-451. doi: 10.1177/1203475417712247. Epub 2017 Jun 5.
Bullous pemphigoid (BP) is an autoimmune bullous disease requiring immunosuppressive therapy. Kaposi sarcoma (KS) is an angioproliferative tumor associated with the opportunistic viral infection human herpes virus 8 (HHV-8). It is a well-known condition associated with longstanding human immunodeficiency virus infection, but it may also occur in the context of iatrogenic immunosuppression.
Although a rare complication, all dermatologists dealing with immunosuppressors must be aware and have a high index of suspicion when a patient presents with rapidly progressive violaceous papules.
We describe an Italian male patient treated for bullous pemphigoid with topical and systemic corticosteroids and mycophenolate mofetil (MMF) who developed multifocal cutaneous KS after a few months of therapy.
To our knowledge, KS onset associated with MMF and corticosteroids intake for BP treatment has not been reported previously. KS associated with iatrogenic immunosuppression can have an aggressive course, and it must be promptly recognised since cessation of immunosuppression therapy can lead to complete resolution. Immune restoration is the key to control this viral infection.
大疱性类天疱疮(BP)是一种需要免疫抑制治疗的自身免疫性大疱性疾病。卡波西肉瘤(KS)是一种与机会性病毒感染人疱疹病毒8(HHV-8)相关的血管增殖性肿瘤。它是一种与长期人类免疫缺陷病毒感染相关的已知疾病,但也可能发生在医源性免疫抑制的情况下。
尽管是一种罕见的并发症,但所有处理免疫抑制剂的皮肤科医生在患者出现快速进展的紫罗兰色丘疹时都必须意识到并保持高度怀疑。
我们描述了一名接受局部和全身皮质类固醇及霉酚酸酯(MMF)治疗大疱性类天疱疮的意大利男性患者,在治疗几个月后发生了多灶性皮肤KS。
据我们所知,此前尚未报道与用于BP治疗的MMF和皮质类固醇摄入相关的KS发病情况。与医源性免疫抑制相关的KS可能具有侵袭性病程,必须迅速识别,因为停止免疫抑制治疗可导致完全缓解。免疫恢复是控制这种病毒感染的关键。